Disproportionate Adverse Event

Disproportionate adverse events represent adverse reactions reported with unexpectedly high frequency relative to expected baseline rates based on historical data or external controls. Spontaneous adverse event reporting systems employ quantitative signal detection methodologies identifying potential safety concerns warranting investigation. Reporting ratios, proportional reporting ratios, and Bayesian confidence propagation neural networks statistically compare observed frequencies to background rates. Disproportionate events trigger regulatory review and potential safety communications.

Contextual evaluation distinguishes true safety signals from reporting artifacts and disease-related events. Temporal relationships between drug administration and adverse event onset inform causality assessment. International collaborations compare disproportionality signals across regulatory databases identifying globally significant safety concerns. Social media monitoring detects emerging adverse event patterns preceding formal regulatory reports. Post-approval pharmacovigilance prioritises investigation of disproportionate events potentially requiring label modifications or market restrictions.